Objective:To investigate the therapeutic effects of nucleoside analogues (acid) and transarterial chemoembolization (TACE) on hepatitis B-related primary liver cancer. Methods:Cases from Guangzhou Eighth People's Hospital were retrospectively analyzed between January 2011 and December 2015. A total of 174 patients were diagnosed with hepatitis B-related primary liver cancer. Pa-tients were categorized based on needs and individual goals. The control group included patients who were classified based on needs (n=72), whereas the research group included patients who were classified based on individual goals (n=102). In the control group, 72 patients underwent TACE. In the research group, 102 patients received nucleoside analogue (acid) and TACE. Results:The two groups did not differ significantly in terms of basic clinical parameters, such as age, sex, tumor size, and laboratory examination (P>0.05). After treatment, the research group was compared with the control group. The liver function of patients in the research group significantly improved (P<0.05). AFP and CA199 levels significantly decreased after 12, 24, and 48 weeks of treatment in the research group (P<0.05). The research group had HBVDNA unpredictable rates of 13.73%, 33.33%, 50.0%, and 76.47%after 4, 12, 24, and 48 weeks of treatment, respectively. The control group had HBVDNA unpredictable rates of 11.11%, 16.67%, 22.22%, and 25.00%after 12, 24, and 48 weeks of treatment, respectively. The HBVDNA unpredictable rate was significantly higher in the control group (P<0.05). The treat-ment effects in the research group were better than that of the control group (P<0.05). In the research group, the 1-and 3-year surviv-al rates were 96.08%and 90.20%, respectively. In the control group, the 1-and 3-year survival rates were 83.33%and 63.89%, respec-tively. The difference in survival rates between the two groups was statistically significant (P<0.05). Conclusion:TACE based on com-bined nucleoside analogue (acid) and antiviral treatment improved ALT levels in patients with hepatitis B-related primary liver cancer and decreased AFP, CA199, and HBVDNA levels. Moreover, the HBVDNA unpredictable rate was modified to facilitate the TACE proce-dure, therefore improving the survival rates of patients and prolonging survival. Therefore, the therapeutic actions of antiviral treat-ment on hepatitis B-related primary liver cancer should be further investigated.%目的：探讨核苷（酸）类似物在乙型肝炎相关原发性肝癌介入栓塞化疗中的作用。方法：回顾性分析广州市第八人民医院2011年1月至2015年12月诊断收治的乙型肝炎相关原发性肝癌患者174例，根据病情需要及患者个人意愿分为对照组72例和研究组102例。对照组采用肝动脉化疗栓塞术（transarterial chemoembolization，TACE术）介入治疗。研究组采用TACE术联合核苷（酸）类似物抗病毒治疗。结果：两组年龄、性别、肿瘤大小及实验室检查等基线资料比较无统计学差异（P>0.05）。治疗后研究组和对照组相比，研究组各时点的肝功能均明显改善（P<0.05）；治疗12、24、48W的AFP及CAl99水平均较对照组明显降低（P<0.05）。研究组乙型肝炎病毒DNA（hepatitis B virus DNA，HBV DNA）不可测率在治疗后4、12、24、48W分别为13.73%、33.33%、50.0%、76.47%，对照组分别为11.11%、16.67%、22.22%、25.00%，研究组治疗12、24、48W HBVDNA不可测率明显高于对照组（P<0.05）。研究组1年、3年生存率分别是96.08%、90.20％，对照组分别为83.33%、63.89%，研究组1、3年生存率明显高于对照组（P<0.05）。研究组治疗的显效率、有效率及总有效率均明显高于对照组（P<0.05）。结论：肝动脉介入栓塞化疗治疗基础上联合核苷（酸）类似物抗病毒治疗可明显改善乙型肝炎相关原发性肝癌患者ALT水平，降低AFP、CA199水平，降低HBVDNA水平，提高HBVDNA不可测率，保障抗肿瘤治疗的顺利进行，从而提高生存率、延长生存期。有必要开展深入研究，以进—步明确抗病毒治疗在肝癌综合治疗中的作用。
展开▼
